KOSDAQBiotech & Pharma056090

CG MedTech

₩4,425▲ 0.57%2026-11-18 close
Market Cap
₩91.4B
Turnover
₩93,770,330
Volume
20K
Shares out.
20.7M
PER
13.4×
PBR
0.9×
EPS
₩310
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Sales Growth Continues, Profit Recovery Under Test

Sales have risen for four straight quarters through the third quarter of 2026 and operating profit has recovered, but swings in quarterly earnings and the timing of new-business revenue remain the key checks.

  1. 1

    Third-quarter 2026 sales were KRW 18.6 billion and operating profit KRW 3.01 billion, the highest of the last five quarters on the filed figures.

  2. 2

    Cumulative nine-month 2026 sales of KRW 46.9 billion equal about 99% of 2025 full-year sales of KRW 47.2 billion, and the company said it expects a new annual sales high (company announcement, November 16, 2026).

  3. 3

    The power-meter subsidiary's third-quarter 2026 sales were KRW 6.8 billion, more than triple the prior-year KRW 2.2 billion, and it swung to an operating profit of KRW 1.2 billion (company announcement).

  4. 4

    The 2025 operating profit of KRW 3.81 billion turned from a 2024 operating loss of KRW 1.12 billion, with a 2025 operating margin of 8.1%.

  5. 5

    Consolidated first-half 2026 operating profit was KRW 570 million, below the prior-year KRW 2.5 billion, so sales growth has not translated directly into profit growth (company announcement).

02

Business structure

CG MedTech was founded in 1997 to make and sell orthopedic body-correction devices and listed on KOSDAQ in 2015. Its core lines are spine and orthopedic implants and bone graft materials, and digital dentistry centered on implant prosthetics has become a recent growth driver.

On a standalone basis, first-half 2026 sales were KRW 17.7 billion, up 35.1% year on year, with domestic sales up 38.3% and overseas sales up 31.8% on the company's internal basis. By product group, spine products rose about 50%, bone graft gel about 41%, and the Novosis trauma line about 94%.

Standalone 2025 sales were KRW 30.1 billion against consolidated sales of KRW 47.2 billion, and the gap comes from subsidiaries. The power-meter subsidiary makes electricity meters and remote-reading communication modules, and its third-quarter 2026 sales of KRW 6.8 billion lifted consolidated results.

In regenerative medicine, the company is building a CDMO business supplying acellular dermal matrix ECM skin boosters, and it signed a CDMO supply contract with a Kolon group pharmaceutical company on June 15, 2026.

Hana Securities noted that most major dermal ECM makers sell under their own brands, while CG MedTech chose contract manufacturing. Its largest shareholder, the parent company, held 40.41% as of September 2026. In June 2026 media reported that IMM PE was close to acquiring a 51% stake in the parent.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩11.3B₩1B8.7%
2025Q4₩11.5B₩300M2.8%
2026Q1₩13B₩200M1.8%
2026Q2₩15.3B₩300M2.2%
2026Q3₩18.6B₩3B16.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩41.2B₩400M-₩18.5B1.0%−32.1%145.2%
2023₩35B-₩1.6B₩1.6B−4.6%2.7%32.1%
2024₩34.6B-₩1.1B₩59,691,629−3.2%0.1%23.6%
2025₩47.2B₩3.8B₩6.5B8.1%6.9%22.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On an annual basis, results moved from losses after 2022 to a profit in 2025. Sales fell from KRW 41.2 billion in 2022 to KRW 35 billion in 2023 (down 15.1% year on year) and KRW 34.6 billion in 2024 (down 1.0%), then recovered to KRW 47.2 billion in 2025 (up 36.4%), the largest year of 2022 through 2025.

Operating profit of KRW 424 million in 2022 turned into an operating loss of KRW 1.62 billion in 2023, and the loss narrowed to KRW 1.12 billion in 2024. The 2025 operating profit of KRW 3.81 billion turned the result positive, with an operating margin of 8.1%, compared with -4.6% in 2023 and -3.2% in 2024.

Net income attributable to controlling shareholders swung from a loss of KRW 18.5 billion in 2022 to KRW 1.63 billion in 2023, fell to KRW 59.69 million in 2024 (down 96.3%), and reached KRW 6.51 billion in 2025 (up 10,801.9%).

Net income including non-controlling interests was also KRW 6.51 billion in 2025, the same value.

The debt-to-equity ratio fell from 145.2% in 2022 to 22.1% in 2025, with total equity of KRW 94.1 billion at end-2025, of which KRW 94 billion belonged to controlling shareholders, and total liabilities of KRW 20.8 billion.

Operating cash flow moved from negative KRW 5.36 billion in 2022 and negative KRW 2.48 billion in 2023 to KRW 1.51 billion in 2024 and KRW 2.61 billion in 2025.

Quarterly sales rose from KRW 11.3 billion in the third quarter of 2025 to KRW 11.5 billion in the fourth quarter (up 1.4% on the quarter), KRW 13 billion in the first quarter of 2026 (up 13.3%), KRW 15.3 billion in the second quarter (up 17.5%), and KRW 18.6 billion in the third quarter (up 21.3%), with four consecutive quarterly increases from the fourth quarter of 2025 through the third quarter of 2026.

Quarterly operating profit was KRW 990 million in the third quarter of 2025, KRW 326 million in the fourth quarter (down 67.1% on the quarter), and KRW 239 million in the first quarter of 2026 (down 26.7%), before KRW 333 million in the second quarter and KRW 3.01 billion in the third quarter (up 803.4% on the quarter and 203.5% year on year).

The company said the third-quarter operating margin was 16%, up 7 percentage points from 9% a year earlier, with the subsidiary's swing to profit as a major contributor.

Controlling-shareholder net income in the same quarter was KRW 1.37 billion, down 11.3% year on year, and the divergence from the operating profit rise should be checked against non-operating items and non-controlling interests in the filing.

Consolidated first-half 2026 operating profit was KRW 570 million, below the prior-year KRW 2.5 billion, which the company attributed to stabilization costs at newly consolidated units, upfront investment, and the timing of revenue recognition on some orders.

05

Industry analysis

In domestic medical devices, demand for musculoskeletal treatment is expected to grow as the population ages, and the company is adding implant capacity and building its tissue-based CDMO, so production capacity is a precondition for its growth.

The company added products approved under the US FDA 510(k) pathway and secured registrations in Latin America and Southeast Asia to widen overseas sales.

In dermal ECM, leading makers typically sell under their own brands through distribution partnerships, while CG MedTech has chosen contract supply, which Hana Securities described as a way to stay out of brand competition.

On overseas expansion, its AATB accreditation from the American Association of Tissue Banks and its supply experience with global device companies were cited as strengths.

The tissue business has first built its production base, including a tissue-processing facility in Seongnam secured in April 2026 and a change permit for its REGEN Hub tissue bank in July 2026.

Sales from the power-meter subsidiary are recognized in sequence as previously received orders proceed according to project schedules. Financial Today reported that a Korea Electric Power order contributed to the subsidiary's third-quarter results.

In cycle terms, the core medical device business is in a growth phase, while the dermal ECM CDMO and regenerative medicine businesses are still at an early stage.

06

Outlook

The company has set a medium-term target of KRW 100 billion in annual sales by 2028 (reported in August 2026). Its growth pillars are expanded spine and orthopedic capacity, overseas sales growth, a digital dentistry value chain, and expansion of tissue products and its hECM CDMO business.

Second-half priorities include stabilizing the production process and raising utilization at the new Uijeongbu plant, recognizing previously received power-meter orders in sequence, and improving operating efficiency at newly consolidated units.

On new businesses, the company said on November 16, 2026 that it expects revenue from ECM skin boosters and other new lines to contribute meaningfully from the fourth quarter.

Hana Securities said in its June 2026 report that the hECM-based dermal CDMO could add customers next year and that it was negotiating with two to three companies.

Cumulative nine-month 2026 sales of KRW 46.9 billion are about 99% of the 2025 annual high, which supports expectations for a new annual sales record in 2026. Full-year operating profit, however, depends on how much the fourth quarter adds to the KRW 36 billion nine-month total.

A completed share transaction at the parent could change the largest shareholder structure, and the timing and status of that deal should be confirmed through disclosure. The 2028 target is the most specific medium-term marker available, and reaching it depends on how quickly new-business revenue is recognized.

07

Valuation

PER
13.4×
PBR
0.9×
ROE
6.8%
EPS
₩310
BPS
₩4,704
Dividend per share
₩0

The share price sits below book value per share, so the premium over net assets is modest. The dividend yield is below the industry average, which means cash returns to shareholders are limited.

On earnings, losses and small profits alternated from 2022 through 2024, so past multiple ranges are hard to compare directly with current earnings power.

Since the return to profit in 2025, the earnings base has built up, and controlling-shareholder net income for the last four quarters totals KRW 6.38 billion on the filed figures.

Quarterly operating profit swings are large, so judging whether that total represents a normal earnings level requires more fourth-quarter 2026 and full-year 2027 results.

Bullish points include a low price relative to net assets and the recovery in operating margin, while bearish points include earnings volatility and price swings typical of a small-cap stock. With the largest shareholder holding over 40%, the free float is also limited.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Sustained sales growth

Cumulative nine-month 2026 sales of KRW 46.9 billion equal about 99% of 2025 full-year sales. Quarterly sales rose for four consecutive quarters from the fourth quarter of 2025 through the third quarter of 2026, and third-quarter sales of KRW 18.6 billion were up 63.8% year on year.

Overseas sales grew 31.8% in the first half of 2026 on the company's internal basis, which points to continued expansion abroad.

Margin recovery

The operating margin was 8.1% in 2025, moving out of loss territory, and third-quarter 2026 operating profit of KRW 3.01 billion was up 203.5% year on year. The company said the same quarter's operating margin was 16%, up 7 percentage points from 9% a year earlier. The subsidiary's swing to profit is also one pillar of the consolidated profit improvement.

New businesses and production base

The company signed a CDMO supply contract with a Kolon group pharmaceutical company and expects new businesses such as ECM skin boosters to contribute from the fourth quarter.

It invested KRW 12.3 billion in buildings and production equipment at the new Uijeongbu plant and set a 2028 target of KRW 100 billion in annual sales. Hana Securities said in its June 2026 report that the hECM CDMO could grow by adding customers.

09

Bear factors

Quarterly earnings volatility

First-quarter 2026 operating profit was KRW 239 million, below KRW 326 million in the fourth quarter of 2025, before jumping to KRW 3.01 billion in the third quarter. Consolidated first-half 2026 operating profit of KRW 570 million fell short of the prior-year KRW 2.5 billion (company announcement). Whether the third-quarter improvement carries into the fourth quarter and beyond remains to be seen.

Gap between operating and net profit

Third-quarter 2026 operating profit rose 203.5% year on year, yet net income attributable to controlling shareholders fell 11.3% to KRW 1.37 billion. In 2024, that net income had dropped 96.3% to KRW 59.69 million.

Whether operating gains consistently reach controlling-shareholder profit needs confirmation over more quarters.

Reliance on subsidiary orders

A considerable part of third-quarter consolidated results came from the power-meter subsidiary, and the company said previously received orders will be recognized in sequence according to project schedules. Delays in that recognition could slow consolidated sales and profit growth. Until utilization at the Uijeongbu plant rises, fixed costs and depreciation could weigh on profit.

10

Risk factors

Earnings volatility

Quarterly operating profit has swung widely, from KRW 326 million in the fourth quarter of 2025 to KRW 239 million in the first quarter of 2026 and KRW 3.01 billion in the third quarter. The company cited higher cost of sales and stabilization costs at new units as factors that weighed on earnings in the first half. Full-year profit could move sharply depending on the timing of revenue recognition on a few quarters' orders.

Licensing and regulation

The tissue-based regenerative medicine business depends on tissue bank licensing and processing facilities.

The company secured a Seongnam facility in April 2026 and received a change permit for its REGEN Hub tissue bank in July 2026, but new product production and CDMO customer contracts must still pass quality review. Overseas sales also depend on country-by-country registration timelines.

Ownership structure and share transfers

The largest shareholder, the parent company, held 40.41% as of September 2026. If the transaction closes, the largest shareholder and management direction could change, and given the small market value, related news could amplify share price swings.

11

What to watch next

  1. March 31, 2027 (annual report filing deadline)

    The 2026 annual report will disclose fourth-quarter and full-year results. The key questions are how much the fourth quarter adds to the KRW 36 billion nine-month operating profit and whether revenue from ECM skin boosters and other new lines appears in those results.

  2. December 31, 2026 (end of fourth quarter 2026)

    Watch whether the power-meter subsidiary's previously received orders keep flowing into fourth-quarter sales and whether utilization at the Uijeongbu plant rises. Because the subsidiary contributed a meaningful share of third-quarter consolidated sales, continuity of these orders matters.

  3. May 15, 2027 (first-quarter quarterly report deadline)

    First-quarter 2027 results will be filed. Whether operating profit returns to the KRW 239 million level of the first quarter of 2026 or holds near the third-quarter 2026 level will be a key gauge of quarterly volatility.

  4. During 2027 (date not set)

    Whether the hECM CDMO business signs additional customers. Hana Securities said in its June 2026 report that it was negotiating with two to three companies.

12

Overall view

CG MedTech swung to an annual profit in 2025, and in 2026 both quarterly sales and operating profit have risen sharply.

On the filed figures, quarterly sales have increased for four consecutive quarters from the fourth quarter of 2025, and operating profit has risen for two consecutive quarters from the second quarter of 2026.

Growth comes from core spine and orthopedic implants and bone graft materials, the power-meter business at the subsidiary, and new businesses such as the dermal ECM-based CDMO.

Bullish factors include a larger sales base, a recovering operating margin, and the subsidiary's return to profit, while bearish factors include volatile quarterly operating profit, controlling-shareholder net income that diverges from operating gains, and reliance on subsidiary orders.

The timing of new-business revenue and the fourth-quarter 2026 results are the first checks on the next phase. The 2028 target of KRW 100 billion in annual sales shows direction, but the gap from the current nine-month pace remains.

Possible changes in the largest shareholder and the progress of licensing for the tissue business are also variables to watch. The share price sits below net asset value, but the earnings base is still short, so the valuation read will depend on how many more periods of results accumulate.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 14 more articles and sources
  1. view.asiae.co.kr
  2. newstown.co.kr
  3. fetv.co.kr
  4. comp.wisereport.co.kr
  5. supple.kr
  6. hanaw.com
  7. thepublic.kr
  8. kyungjeilbo.com
  9. view.asiae.co.kr
  10. ftoday.co.kr
  11. newsclaim.co.kr
  12. newsprime.co.kr
  13. thevaluenews.co.kr
  14. kr.investing.com

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis